Digital ischaemia secondary to adalimumab-induced antiphospholipid syndrome

Cheemalavagu, Shashank; McCoy, Sara S.; Knight, Jason S.

doi:10.1136/bcr-2019-232907

Cited by 9 publications

(2 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This trial should clarify the role of anti-TNF therapy for this APS manifestation. It is important to note that there are reported cases of the development 135,136 or exacerbation 137 of APS while using anti TNF therapy. These drugs currently have no role in other disease manifestations and may have deleterious effects.…”

Section: Biologics: Rituximab Belimumab and Anti-tnf Therapiesmentioning

confidence: 99%

16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends

Cohen

Cuadrado

Erkan

et al. 2020

Lupus

Self Cite

101

112

View full text Add to dashboard Cite

Antiphospholipid syndrome (APS), an acquired autoimmune thrombophilia, is characterised by thrombosis and/or pregnancy morbidity in association with persistent antiphospholipid antibodies. The 16th International Congress on Antiphospholipid Antibodies Task Force on APS Treatment Trends reviewed the current status with regard to existing and novel treatment trends for APS, which is the focus of this Task Force report. The report addresses current treatments and developments since the last report, on the use of direct oral anticoagulants in patients with APS, antiplatelet agents, adjunctive therapies (hydroxychloroquine, statins and vitamin D), targeted treatment including rituximab, belimumab, and anti-TNF agents, complement inhibition and drugs based on peptides of beta-2-glycoprotein I. In addition, the report summarises potential new players, including coenzyme Q10, adenosine receptor agonists and adenosine potentiation. In each case, the report provides recommendations for clinicians, based on the current state of the art, and suggests a clinical research agenda. The initiation and development of appropriate clinical studies requires a focus on devising suitable outcome measures, including a disease activity index, an optimal damage index, and a specific quality of life index.

show abstract

Section: Biologics: Rituximab Belimumab and Anti-tnf Therapiesmentioning

confidence: 99%

16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends

Cohen

Cuadrado

Erkan

et al. 2020

Lupus

Self Cite

101

112

View full text Add to dashboard Cite

show abstract

“…This suggests that obinutuzumab might serve as a treatment option for APS cases that are resistant to rituximab. Belimumab [ 119 ], eculizumab [ 120 , 121 ], and TNF-α blockers such as adalimumab [ 122 , 123 ] have been reported to be effective in some cases, but additional data on their efficacy and safety profiles are needed for their routine clinical use.…”

Section: Future Perspectives In Antiphospholipid Syndrome Research An...mentioning

confidence: 99%

Management of Cardiovascular Complications in Antiphospholipid Syndrome: A Narrative Review with a Focus on Older Adults

Bernardi,

Spadafora,

Andaloro

et al. 2024

JCM

View full text Add to dashboard Cite

Antiphospholipid syndrome (APS), also known as Hughes syndrome, is an acquired autoimmune and procoagulant condition that predisposes individuals to recurrent thrombotic events and obstetric complications. Central is the role of three types of antiphospholipid antibodies that target phospholipid-binding proteins: lupus anticoagulant (LAC), anti-β2-glycoprotein I (β2-GPI-Ab), and anti-cardiolipin (aCL). Together with clinical data, these antibodies are the diagnostic standard. However, the diagnosis of APS in older adults may be challenging and, in the diagnostic workup of thromboembolic complications, it is an underestimated etiology. The therapeutic management of APS requires distinguishing two groups with differential risks of thromboembolic complications. The standard therapy is based on low-dose aspirin in the low-risk group and vitamin K antagonists in the high-risk group. The value of direct oral anticoagulants is currently controversial. The potential role of monoclonal antibodies is investigated. For example, rituximab is currently recommended in catastrophic antiphospholipid antibody syndrome. Research is ongoing on other monoclonal antibodies, such as daratumumab and obinutuzumab. This narrative review illustrates the pathophysiological mechanisms of APS, with a particular emphasis on cardiovascular complications and their impact in older adults. This article also highlights advancements in the diagnosis, risk stratification, and management of APS.

show abstract

Anti-phospholipid syndrome leading to digital ischaemia and rare organ complications in systemic sclerosis and related disorders

Chatterjee

Pauling

2020

Clin Rheumatol

View full text Add to dashboard Cite

show abstract

Digital ischaemia secondary to adalimumab-induced antiphospholipid syndrome

Cited by 9 publications

References 22 publications

16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends

16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends

Management of Cardiovascular Complications in Antiphospholipid Syndrome: A Narrative Review with a Focus on Older Adults

Anti-phospholipid syndrome leading to digital ischaemia and rare organ complications in systemic sclerosis and related disorders

Contact Info

Product

Resources

About